A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human

PK studies in NHPs. We also report for the first time the use of an immunocompromised version of the Tg276 model to mitigate anti-drug antibody responses. Our findings show that the Tg276 hemizygous model exhibits a translational performance equal to, and in some cases superior to, that of the Tg32 homozygous strain and the NHP, specifically, in terms of predicted clearance. These insights support the Tg276 model as a valuable tool for early-stage antibody screening and lead optimization in preclinical PK evaluation.